Premium
Is the Dx for Welfare Rx?
Author(s) -
Ridinger M H T
Publication year - 2007
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/sj.clpt.6100196
Subject(s) - pharmacotherapy , champion , welfare , depression (economics) , anxiety , clinical pharmacology , medicine , psychiatry , intensive care medicine , political science , economics , pharmacology , law , macroeconomics
Welfare recipients in the United States are three times as likely to suffer from depression and anxiety as average Americans. Although affordable pharmacotherapy options are readily available in more affluent parts of society, welfare programs are ineffective in facilitating diagnosis and therapy that could help the affected improve their lives and even ultimately become gainfully employed and off taxpayersupported welfare programs. To the benefit of all, more “bang for the buck” is within reach with common pharmacotherapy, but the question remains: who will wake up and champion the obvious? Clinical Pharmacology & Therapeutics (2007) 81 , 624–626. doi: 10.1038/sj.clpt.6100196